Abstract
Variability in exposure to a drug leads to variability in the clinical response across a patient patient population (Rowland et al. 1985). Estimating the variability of the PK (pharmacokinetics) across a patient population requires data obtained from a large study, typically including more than 100 patients. For ethical and practical reasons, pharmacokinetic properties of a drug are difficult to study in large numbers of patients using the traditional approach.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Beal S, Sheiner L (1992) NONMEM user guide. University of California, San Francisco
Efron B (1981) Nonparametric estimates of standard error: the jackknife, the bootstrap and other methods. Biometrika 68:589–599
FDA (ed) (1999) Guidance for industry: population pharmacokinetics. CP1
Grasela T, Sheiner L (1991) Pharmacostatistical modeling for observational data. J Pharmacokin Biopharm 19(3):25S–37S
Jelliffe R, Gomis P, Schumitzky A (1990) A population model of genamicin made with a new nonparametric EM algorithm. Technical report 90-4, Laboratory of Applied Pharmacokinetics. University of Southern California School of Medicine, Los Angeles
Mathsoft (ed) (2002) S-Plus 6.0 for UNIX users guide. Mathsoft, Seattle
Press W, Flannery B, Teukolsky S, Vetterling W (1988) Numerical recipes in C, the art of scientific computing. Cambridge University Press, Cambridge, pp 551–553
Rowland M, Sheiner L, Steimer J (eds) (1985) Variability in drug therapy: description, estimation, and control. Raven, New York
Sheiner L (1997) Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61:275–291
Sheiner L, Beal S (1980) Evaluation of methods for estimating population pharmacokinetic parameters I Michaelis–Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 8(6):553–571
Sheiner L, Grasela T (1991) An introduction to mixed effect modeling: concepts, definitions, and justification. J Pharmacokinet Biopharm 19(3):11S–24S
Sheiner L, Rosenberg B, Barathe V (1977) Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 5(5):445–479
Sheiner L, Stanski D, Vozeh S et al (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25(3):358–371
Steimer J, Mallet A, Mentre F (1985) Estimating interindividual pharmacokinetic variability. In: Rowland M et al (eds) Variability in drug therapy: description, estimation and control. Raven, New York
Tanigawara Y, Nomura H, Kagimoto N, Okumura K, Hori R (1995) Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. Biol Pharm Bull 18(2):315–320
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Weber, W., Rüppel, D. (2013). Population Pharmacokinetics. In: Vogel, H.G., Maas, J., Hock, F.J., Mayer, D. (eds) Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-25240-2_50
Download citation
DOI: https://doi.org/10.1007/978-3-642-25240-2_50
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-25239-6
Online ISBN: 978-3-642-25240-2
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences